Portal de Periódicos da CAPES

Cardiovascular Side Effects of Diethylstilbestrol, Cyproterone Acetate, Medroxyprogesterone Acetate and Estramustine Phosphate Used for the Treatment of Advanced Prostatic Cancer: Results from European Organization for Research on Treatment of Cancer Trials 30761 and 30762

1986; Lippincott Williams & Wilkins; Volume: 135; Issue: 2 Linguagem: Inglês

10.1016/s0022-5347(17)45620-5

1527-3792

H. J. de Voogt, Philip H. Smith, M. Pavone‐Macaluso, Marleen de Pauw, Stefan Suciu,

Hormonal and reproductive studies

No AccessJournal of Urology1 Feb 1986Cardiovascular Side Effects of Diethylstilbestrol, Cyproterone Acetate, Medroxyprogesterone Acetate and Estramustine Phosphate Used for the Treatment of Advanced Prostatic Cancer: Results from European Organization for Research on Treatment of Cancer Trials 30761 and 30762 Herman J. de Voogt, Philip H. Smith, Michele Pavone-Macaluso, Marleen de Pauw, Stefan Suciu, and Members of the European Organization for Research on Treatment of Cancer Urological Group Herman J. de VoogtHerman J. de Voogt More articles by this author , Philip H. SmithPhilip H. Smith More articles by this author , Michele Pavone-MacalusoMichele Pavone-Macaluso More articles by this author , Marleen de PauwMarleen de Pauw More articles by this author , Stefan SuciuStefan Suciu More articles by this author , and Members of the European Organization for Research on Treatment of Cancer Urological Group More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)45620-5AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Two randomized trials were started in 1976 by the European Organization for Research on Treatment of Cancer urological group. Trial 30761 compared 1mg. diethylstilbestrol orally 3 times daily to 250mg. oral cyproterone acetate daily and to 500mg. medroxyprogesterone acetate intramuscularly 3 times weekly for 8 weeks, then 200mg. orally daily. Trial 30762 compared 3mg. diethylstilbestrol to 560mg. estramustine phosphate orally for 8 weeks and then 280mg. daily. The 239 patients in study 30761 and 226 in study 30762 were evaluated for cardiovascular toxicity during treatment. Various types of side effects (fluid retention, hypertension, electrocardiographic changes, myocardial infarction and thromboembolic disease) and their degrees of severity were analyzed. In both studies the most frequent type of cardiovascular toxicity was represented by fluid retention. Cardiovascular toxicity as a whole was higher with diethylstilbestrol than with estramustine phosphate or medroxyprogesterone acetate therapy, and was the lowest with cyproterone acetate therapy. The risk of severe cardiovascular complications developing was the highest during the first 6 months of treatment. Increasing age, body weight greater than 75kg. and, especially, the presence of previous cardiovascular disease represented adverse factors in the development of cardiovascular toxicity. © 1986 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited ByBeer T, Bland L, Bussiere J, Neiss M, Wersinger E, Garzotto M, Ryan C and Janowsky J (2018) Testosterone Loss and Estradiol Administration Modify Memory in MenJournal of Urology, VOL. 175, NO. 1, (130-135), Online publication date: 1-Jan-2006.SCIARRA A, BOSMAN C, MONTI G, GENTILE V, GOMEZ A, CICCARIELLO M, PASTORE A, SALVATORI G, FATTORE F and DI SILVERIO F (2018) SOMATOSTATIN ANALOGUES AND ESTROGENS IN THE TREATMENT OF ANDROGEN ABLATION REFRACTORY PROSTATE ADENOCARCINOMAJournal of Urology, VOL. 172, NO. 5, (1775-1783), Online publication date: 1-Nov-2004.KLOTZ L, McNEILL I and FLESHNER N (2018) A PHASE 1-2 TRIAL OF DIETHYLSTILBESTROL PLUS LOW DOSE WARFARIN IN ADVANCED PROSTATE CARCINOMAJournal of Urology, VOL. 161, NO. 1, (169-172), Online publication date: 1-Jan-1999.de Voogt H, Suciu S, Sylvester R, Pavone-Macaluso M, Smith P and de Pauw M (2018) Multivariate Analysis of Prognostic Factors in Patients with Advanced Prostatic Cancer: Results from 2 European Organization for Research on Treatment of Cancer TrialsJournal of Urology, VOL. 141, NO. 4, (883-888), Online publication date: 1-Apr-1989.Goldenberg S, Bruchovsky N, Rennie P and Coppin C (2018) The Combination of Cyproterone Acetate and Low Dose Diethylstilbestrol in the Treatment of Advanced Prostatic CarcinomaJournal of Urology, VOL. 140, NO. 6, (1460-1465), Online publication date: 1-Dec-1988.Pavone-Macaluso M, de Voogt H, Viggiano G, Barasolo E, Lardennois B, de Pauw M and Sylvester R (2018) Comparison of Diethylstilbestrol, Cyproterone Acetate and Medroxyprogesterone Acetate in the Treatment of Advanced Prostatic Cancer: Final Analysis of a Randomized Phase III Trial of the European Organization for Research on Treatment of Cancer Urological GroupJournal of Urology, VOL. 136, NO. 3, (624-631), Online publication date: 1-Sep-1986. Volume 135Issue 2February 1986Page: 303-307 Advertisement Copyright & Permissions© 1986 by The American Urological Association Education and Research, Inc.MetricsAuthor Information Herman J. de Voogt More articles by this author Philip H. Smith More articles by this author Michele Pavone-Macaluso More articles by this author Marleen de Pauw More articles by this author Stefan Suciu More articles by this author Members of the European Organization for Research on Treatment of Cancer Urological Group More articles by this author Expand All Advertisement Loading ...